Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis
Ontology highlight
ABSTRACT: We here analyzed CSF and blood from two relapsing-remitting multiple sclerosis (RRMS) patients early after peripheral leukocyte depletion with the anti-CD52 antibody alemtuzumab compared to untreated RRMS and control patients using single cell RNA-sequencing.
ORGANISM(S): Homo sapiens
PROVIDER: GSE227954 | GEO | 2023/04/14
REPOSITORIES: GEO
ACCESS DATA